Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 12/2010

01.12.2010 | 2010 SSAT Plenary Presentation

Insulin, Leptin, and Tumoral Adipocytes Promote Murine Pancreatic Cancer Growth

verfasst von: Patrick B. White, Eben M. True, Kathryn M. Ziegler, Sue S. Wang, Deborah A. Swartz-Basile, Henry A. Pitt, Nicholas J. Zyromski

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Obesity accelerates development and growth of human pancreatic cancer. We recently reported similar findings in a novel murine model of pancreatic cancer in congenitally obese mice. The current experiments were designed to evaluate the effects of diet-induced obesity on pancreatic cancer growth.

Methods

Thirty C57BL/6J female mice were fed either control 10% fat (n = 10) or 60% fat diet (n = 20) starting at age 6 weeks. At 11 weeks, 2.5 × 105 PAN02 murine pancreatic cancer cells were inoculated. After 6 weeks, tumors were harvested. Serum adiponectin, leptin, insulin, and glucose concentrations were measured. Tumor proliferation, apoptosis, adipocyte content, and tumor-infiltrating lymphocytes were evaluated.

Results

The diet-induced obesity diet led to significant weight gain (control 21.3 ± 0.6 g; diet-induced obesity 23.1 ± 0.5 g; p = 0.03). Mice heavier than 23.1 g were considered “Overweight.” Tumors grew significantly larger in overweight (1.3 ± 0.3 g) compared to lean (0.5 ± 0.2 g; p = 0.03) mice; tumor size correlated positively with body weight (R = 0.56; p < 0.02). Serum leptin (3.1 ± 0.7 vs. 1.4 ± 0.2 ng/ml) and insulin (0.5 ± 0.2 vs. 0.18 ± 0.02 ng/ml) were significantly greater in overweight mice. Tumor proliferation, apoptosis, and tumor adipocyte volume were similar. T and B lymphocytes were observed infiltrating tumors from lean and overweight mice in similar number.

Conclusion

These data show that diet-induced obesity accelerates the growth of murine pancreatic cancer.
Literatur
1.
Zurück zum Zitat Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in Obesity Among US Adults, 1999–2008. JAMA. 303(3):235–241. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in Obesity Among US Adults, 1999–2008. JAMA. 303(3):235–241.
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin, 2009: 59(4):225–49CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin, 2009: 59(4):225–49CrossRefPubMed
3.
Zurück zum Zitat Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 2004. 4(8):579–591.CrossRefPubMed Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer, 2004. 4(8):579–591.CrossRefPubMed
4.
Zurück zum Zitat Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PW, Evans DB. Influence of Obesity on Cancer-Related Outcomes After Pancreatectomy to Treat Pancreatic Adenocarcinoma. Arch Surg, 2009. 144(3): 216–221.CrossRefPubMed Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, Lee JE, Crane CH, Pisters PW, Evans DB. Influence of Obesity on Cancer-Related Outcomes After Pancreatectomy to Treat Pancreatic Adenocarcinoma. Arch Surg, 2009. 144(3): 216–221.CrossRefPubMed
5.
Zurück zum Zitat Zyromski NJ, Mathur A, Pitt HA, Wade TE, Wang S, Nakshatri P, Swartz-Basile DA, Nakshatri H. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery, 2009. 146(2): 258–263.CrossRefPubMed Zyromski NJ, Mathur A, Pitt HA, Wade TE, Wang S, Nakshatri P, Swartz-Basile DA, Nakshatri H. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery, 2009. 146(2): 258–263.CrossRefPubMed
6.
Zurück zum Zitat Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC. Depletion of CD4 + CD25+ Regulatory T Cells Promotes a Tumor-Specific Immune Response in Pancreas Cancer-Bearing Mice. Annals of Surgical Oncology, 2006. 13(9): 1252–1258.CrossRefPubMed Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ, Goedegebuure PS, Linehan DC. Depletion of CD4 + CD25+ Regulatory T Cells Promotes a Tumor-Specific Immune Response in Pancreas Cancer-Bearing Mice. Annals of Surgical Oncology, 2006. 13(9): 1252–1258.CrossRefPubMed
7.
Zurück zum Zitat Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother, 2006. 29(4): 416–24.CrossRefPubMed Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother, 2006. 29(4): 416–24.CrossRefPubMed
8.
Zurück zum Zitat Janik P, Briand P, Hartmann NR. The Effect of Estrone-Progesterone Treatment on Cell Proliferation Kinetics of Hormone-dependent GR Mouse Mammary Tumors. Cancer Res, 1975. 35(12): 3698–3704.PubMed Janik P, Briand P, Hartmann NR. The Effect of Estrone-Progesterone Treatment on Cell Proliferation Kinetics of Hormone-dependent GR Mouse Mammary Tumors. Cancer Res, 1975. 35(12): 3698–3704.PubMed
9.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985. 28(7): 412–9.CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985. 28(7): 412–9.CrossRefPubMed
10.
Zurück zum Zitat Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res, 2007. 174: 49–53.CrossRefPubMed Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res, 2007. 174: 49–53.CrossRefPubMed
11.
Zurück zum Zitat Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers. JAMA, 2005. 294(22): 2872–2878.CrossRefPubMed Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers. JAMA, 2005. 294(22): 2872–2878.CrossRefPubMed
12.
Zurück zum Zitat Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 2006. 6(10): 772–783.CrossRefPubMed Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol, 2006. 6(10): 772–783.CrossRefPubMed
13.
Zurück zum Zitat Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol, 2000. 68(4): 437–446.PubMed Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol, 2000. 68(4): 437–446.PubMed
14.
Zurück zum Zitat Garofalo C, Surmacz E. Leptin and cancer. Journal of Cellular Physiology, 2006. 207(1): 12–22.CrossRefPubMed Garofalo C, Surmacz E. Leptin and cancer. Journal of Cellular Physiology, 2006. 207(1): 12–22.CrossRefPubMed
15.
Zurück zum Zitat Pezzilli R, Mariani A, Gabbrielli A, Morselli-Labate AM, Barassi A. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scandinavian Journal of Gastroenterology, 2009. 45(1): 93–99.CrossRef Pezzilli R, Mariani A, Gabbrielli A, Morselli-Labate AM, Barassi A. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scandinavian Journal of Gastroenterology, 2009. 45(1): 93–99.CrossRef
16.
Zurück zum Zitat Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, Karmaniolas K, Pelecanos N, Tseleni-Balafouta S, Dionyssiou-Asteriou A, Mantzoros CS. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study. Cancer Causes and Control, 2009. 20(5): 625–633.CrossRefPubMed Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, Karmaniolas K, Pelecanos N, Tseleni-Balafouta S, Dionyssiou-Asteriou A, Mantzoros CS. Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case–control study. Cancer Causes and Control, 2009. 20(5): 625–633.CrossRefPubMed
17.
Zurück zum Zitat Okuya S, Tanabe K, Tanizawa Y, Oka Y. Leptin Increases the Viability of Isolated Rat Pancreatic Islets by Suppressing Apoptosis. Endocrinology, 2001. 142(11): 4827–4830.CrossRefPubMed Okuya S, Tanabe K, Tanizawa Y, Oka Y. Leptin Increases the Viability of Isolated Rat Pancreatic Islets by Suppressing Apoptosis. Endocrinology, 2001. 142(11): 4827–4830.CrossRefPubMed
18.
Zurück zum Zitat Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro. Journal of Surgical Research, 2003. 113(1): 50–55.CrossRefPubMed Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro. Journal of Surgical Research, 2003. 113(1): 50–55.CrossRefPubMed
19.
Zurück zum Zitat Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression. Cancer Res, 2008. 68(3): 918–926.CrossRefPubMed Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancer-Associated Stromal Fibroblasts Promote Pancreatic Tumor Progression. Cancer Res, 2008. 68(3): 918–926.CrossRefPubMed
20.
Zurück zum Zitat Farrow B, Albo D, Berger DH, The Role of the Tumor Microenvironment in the Progression of Pancreatic Cancer. Journal of Surgical Research, 2008. 149(2): 319–328.CrossRefPubMed Farrow B, Albo D, Berger DH, The Role of the Tumor Microenvironment in the Progression of Pancreatic Cancer. Journal of Surgical Research, 2008. 149(2): 319–328.CrossRefPubMed
21.
Zurück zum Zitat Halberg N, Wernstedt-Asterholm I, Scherer PE, The Adipocyte as an Endocrine Cell. Endocrinology & Metabolism Clinics of North America, 2008. 37(3): 753–768.CrossRef Halberg N, Wernstedt-Asterholm I, Scherer PE, The Adipocyte as an Endocrine Cell. Endocrinology & Metabolism Clinics of North America, 2008. 37(3): 753–768.CrossRef
22.
Zurück zum Zitat Ziegler KM, Considine RV, True EM, Wang SS, Swartz-Basile DA, Pitt HA, Zyromski NJ Adipocytes enhance pancreatic cancer growth via a hepatocyte growth factor (HGF)-mediated mechanism. Surgery, 2010, in press. Ziegler KM, Considine RV, True EM, Wang SS, Swartz-Basile DA, Pitt HA, Zyromski NJ Adipocytes enhance pancreatic cancer growth via a hepatocyte growth factor (HGF)-mediated mechanism. Surgery, 2010, in press.
23.
Zurück zum Zitat Samama P, Rumennik L, Grippo JF. The melanocortin receptor MCR4 controls fat consumption. Regulatory Peptides, 2003. 113(1–3): 85–88.CrossRefPubMed Samama P, Rumennik L, Grippo JF. The melanocortin receptor MCR4 controls fat consumption. Regulatory Peptides, 2003. 113(1–3): 85–88.CrossRefPubMed
24.
Zurück zum Zitat Zhang Y, Kilroy GE, Henagan TM, Prpic-Uhing V, Richards WG, Bannon, AW, Mynatt RL, Gettys TW. Targeted deletion of melanocortin receptor subtypes 3 and 4, but not CART, alters nutrient partitioning and compromises behavioral and metabolic responses to leptin. FASEB J., 2005. 19(11): 1482–1491.CrossRefPubMed Zhang Y, Kilroy GE, Henagan TM, Prpic-Uhing V, Richards WG, Bannon, AW, Mynatt RL, Gettys TW. Targeted deletion of melanocortin receptor subtypes 3 and 4, but not CART, alters nutrient partitioning and compromises behavioral and metabolic responses to leptin. FASEB J., 2005. 19(11): 1482–1491.CrossRefPubMed
25.
Zurück zum Zitat Bergen HT, Mizuno TM, Taylor J, Mobbs CV. Hyperphagia and Weight Gain after Gold-Thioglucose: Relation to Hypothalamic Neuropeptide Y and Proopiomelanocortin. Endocrinology, 1998. 139(11): 4483–4488.CrossRefPubMed Bergen HT, Mizuno TM, Taylor J, Mobbs CV. Hyperphagia and Weight Gain after Gold-Thioglucose: Relation to Hypothalamic Neuropeptide Y and Proopiomelanocortin. Endocrinology, 1998. 139(11): 4483–4488.CrossRefPubMed
26.
Zurück zum Zitat Meister B, Ceccatelli S, Hökfelt T, Andén NE, Andén M, Theodorsson E. Neurotransmitters, neuropeptides and binding sites in the rat mediobasal hypothalamus: effects of monosodium glutamate (MSG) lesions. Exp Brain Res, 1989. 76(2): 343–68.CrossRefPubMed Meister B, Ceccatelli S, Hökfelt T, Andén NE, Andén M, Theodorsson E. Neurotransmitters, neuropeptides and binding sites in the rat mediobasal hypothalamus: effects of monosodium glutamate (MSG) lesions. Exp Brain Res, 1989. 76(2): 343–68.CrossRefPubMed
27.
Zurück zum Zitat Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.Cancer Cell, 2005. 7(5): 469–483.CrossRefPubMed Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.Cancer Cell, 2005. 7(5): 469–483.CrossRefPubMed
Metadaten
Titel
Insulin, Leptin, and Tumoral Adipocytes Promote Murine Pancreatic Cancer Growth
verfasst von
Patrick B. White
Eben M. True
Kathryn M. Ziegler
Sue S. Wang
Deborah A. Swartz-Basile
Henry A. Pitt
Nicholas J. Zyromski
Publikationsdatum
01.12.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 12/2010
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1349-x

Weitere Artikel der Ausgabe 12/2010

Journal of Gastrointestinal Surgery 12/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.